Relay Therapeutics, Inc. (RLAY) — SEC Filings
Relay Therapeutics, Inc. (RLAY) — 27 SEC filings. Latest: 10-Q (Nov 6, 2025). Includes 12 8-K, 6 10-Q, 5 SC 13G/A.
View Relay Therapeutics, Inc. on SEC EDGAR
Overview
Relay Therapeutics, Inc. (RLAY) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Relay Therapeutics, Inc. reported a net loss of $74.1 million for the three months ended September 30, 2025, an improvement from the $88.1 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $221.6 million, compared to $261.7 million in the pri
Sentiment Summary
Across 27 filings, the sentiment breakdown is: 2 bullish, 3 bearish, 22 neutral. The dominant filing sentiment for Relay Therapeutics, Inc. is neutral.
Filing Type Overview
Relay Therapeutics, Inc. (RLAY) has filed 6 10-Q, 12 8-K, 2 DEF 14A, 1 10-K, 5 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (27)
Risk Profile
Risk Assessment: Of RLAY's 20 recent filings, 2 were flagged as high-risk, 9 as medium-risk, and 9 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $8.36M |
| Net Income | -$221.6M |
| EPS | -$1.28 |
| Debt-to-Equity | N/A |
| Cash Position | $91.56M |
| Operating Margin | N/A |
| Total Assets | $635.75M |
| Total Debt | $0.00M |
Key Executives
- Sarah Michaels
Industry Context
Relay Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel therapeutics. The industry is characterized by long development cycles, significant R&D investment, and a high rate of failure. Success hinges on innovation, clinical trial outcomes, and securing substantial funding for pipeline advancement.
Top Tags
biotech (5) · 10-Q (4) · 8-K (3) · financials (3) · Biotechnology (2) · Clinical Trials (2) · Net Loss (2) · Cash Burn (2) · corporate-governance (2) · 8-k (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $221.6M | For the nine months ended September 30, 2025, a 15.4% improvement from $261.7M in 2024. |
| Total Revenue | $8.36M | For the nine months ended September 30, 2025, down from $10.01M in 2024. |
| Research and Development Expenses | $206.0M | For the nine months ended September 30, 2025, an 18% decrease from $251.0M in 2024. |
| Cash and Cash Equivalents | $91.56M | As of September 30, 2025, a decrease from $124.29M at December 31, 2024. |
| Investments | $504.87M | As of September 30, 2025, a decrease from $657.04M at December 31, 2024. |
| Accumulated Deficit | $1.96B | As of September 30, 2025, indicating significant historical losses. |
| Shares Outstanding | 172,631,268 | As of September 30, 2025, reflecting dilution from prior offerings. |
| Net Loss Per Share (Q3 2025) | $0.43 | Improved from $0.63 in Q3 2024. |
| Research and Development Expense | $84.2M | Increased from $72.5M in Q2 2024, reflecting continued pipeline investment. |
| Revenue | $13.7M | Decreased from $15.2M in Q2 2024, showing a decline in collaboration income. |
| Cash and Investments | $650.3M | Decreased from $780.1M at year-end 2024, highlighting significant cash burn. |
| Cash Burn (6 months) | $129.8M | Represents the decrease in cash and investments from Dec 31, 2024, to June 30, 2025. |
| SEC File Number | 001-39385 | Relay Therapeutics' SEC filing identifier |
| IRS Employer Identification No. | 47-3923475 | Relay Therapeutics' tax identification number |
| Commission File Number | 001-39385 | Identifies the company's filing with the SEC. |
Frequently Asked Questions
What are the latest SEC filings for Relay Therapeutics, Inc. (RLAY)?
Relay Therapeutics, Inc. has 27 recent SEC filings from Jan 2024 to Nov 2025, including 12 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RLAY filings?
Across 27 filings, the sentiment breakdown is: 2 bullish, 3 bearish, 22 neutral. The dominant sentiment is neutral.
Where can I find Relay Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Relay Therapeutics, Inc. (RLAY) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Relay Therapeutics, Inc.?
Key financial highlights from Relay Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RLAY?
The investment thesis for RLAY includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Relay Therapeutics, Inc.?
Key executives identified across Relay Therapeutics, Inc.'s filings include Sarah Michaels.
What are the main risk factors for Relay Therapeutics, Inc. stock?
Of RLAY's 20 assessed filings, 2 were flagged high-risk, 9 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Relay Therapeutics, Inc.?
Forward guidance and predictions for Relay Therapeutics, Inc. are extracted from SEC filings as they are enriched.